Computer-aided Affinity Enhancement of a Cross-reactive Antibody against Dengue Virus Envelope Domain III

被引:0
作者
Nisha Amarnath Jonniya
Sayan Poddar
Subhasmita Mahapatra
Parimal Kar
机构
[1] Indian Institute of Technology Indore,Department of Biosciences and Biomedical Engineering
[2] University of California San Diego,Department of Pharmacology
来源
Cell Biochemistry and Biophysics | 2023年 / 81卷
关键词
Dengue; Molecular dynamics simulations; Computational mutagenesis; Binding energy; Affinity maturation;
D O I
暂无
中图分类号
学科分类号
摘要
The dengue virus (DENV), composed of four distinct but serologically related Flaviviruses, causes the most important emerging viral disease, with nearly 400 million infections yearly. Currently, there are no approved therapies. Although DENV infection induces lifelong immunity against the same serotype, the antibodies raised contribute to severe disease in heterotypic infections. Therefore, understanding the mechanism of DENV neutralization by antibodies is crucial in the design of vaccines against all serotypes. This study reports a comparative structural and energetic analysis of the monoclonal antibody (mAb) 4E11 in complex with its target domain III of the envelope protein for all four DENV serotypes. We use extensive replica molecular dynamics simulations in conjunction with the binding free energy calculations. Further single point and double mutations were designed through computational site-directed mutagenesis and observed that the re-engineered antibody exhibits high affinity to binding and broadly neutralizing activity against serotypes. Our results showed improved binding affinity by the gain of enthalpy, which could be attributed to the stabilization of salt-bridge and hydrogen bond interactions at the antigen-antibody interface. The findings provide valuable results in understanding the structural dynamics and energetic contributions that will be helpful to the design of high-affinity antibodies against dengue infections.
引用
收藏
页码:737 / 755
页数:18
相关论文
共 300 条
[1]  
Monath TP(1994)Dengue: the risk to developed and developing countries Proceedings of the National Academy of Sciences 91 2395-2400
[2]  
Bhatt S(2013)The global distribution and burden of dengue Nature 496 504-507
[3]  
Gething PW(2016)The global economic burden of dengue: a systematic analysis The Lancet Infectious Diseases 16 935-941
[4]  
Brady OJ(2004)Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses Nature Medicine 10 S98-S109
[5]  
Messina JP(1952)Research on Dengue during World War II 1 The American Journal of Tropical Medicine and Hygiene 1 30-50
[6]  
Farlow AW(1984)RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND American Journal of Epidemiology 120 653-669
[7]  
Moyes CL(1977)Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody Journal of Experimental Medicine 146 201-217
[8]  
Hay SI(2014)Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial The Lancet 384 1358-1365
[9]  
Shepard DS(2012)Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial The Lancet 380 1559-1567
[10]  
Undurraga EA(2015)Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America New England Journal of Medicine 372 113-123